Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,015
Total Claims
$1.1M
Drug Cost
871
Beneficiaries
$1,309
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-7%
Cost per patient vs peers
$1,309 vs $1,411 avg
-10%
Brand preference vs peers
9.6% vs 10.6% avg
Brand vs Generic
Brand: 2,109 claims · $817K
Generic: 19,836 claims · $321K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 383 | $286K |
| Rivaroxaban | 126 | $86K |
| Sitagliptin Phos/Metformin Hcl | 111 | $68K |
| Apixaban | 64 | $42K |
| Levothyroxine Sodium | 582 | $37K |
| Sitagliptin Phosphate | 52 | $36K |
| Insulin Glargine,hum.Rec.Anlog | 84 | $30K |
| Empagliflozin | 39 | $30K |
| Dulaglutide | 31 | $29K |
| Insulin Glargine/Lixisenatide | 27 | $23K |
| Insulin Lispro | 68 | $20K |
| Rosuvastatin Calcium | 1,130 | $16K |
| Diclofenac Potassium | 557 | $16K |
| Gabapentin | 1,811 | $15K |
| Losartan Potassium | 1,211 | $14K |
Prescribing Profile
Patient Profile
72
Avg Age
65%
Female
3.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data